rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CORT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      What Is Driving The Move In Corcept Therapeutics Stock?
      15h agoYahoo FinanceCORT
      Corcept reports 8-year response in vulvar cancer case study
      Nov 16Investing.comCORT
      Can You Justify Buying Corcept Stock Today?
      Nov 6Yahoo FinanceCORT
      Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build

      Corcept Therapeutics (CORT) just delivered a sharp jump in profitability in its third quarter report, with net income of US$126.78 million and diluted EPS of US$1.01 from continuing operations. That profit jump landed against a sharp reset in sentiment, with Corcept Therapeutics’ share price down 40.11% over the past month and 35.33% over 90 days, even after an 87.51% year-to-date share price gain and a 186.18% three-year total shareholder return that points to strong long-run backing for the...

      Nov 6Yahoo FinanceCORT
      Top 3 Health Care Stocks You'll Regret Missing In Q4
      Nov 5BenzingaALNYCORT
      Corcept president of oncology Vieira sells $674,068 in stock
      Nov 5Investing.comCORT
      Corcept Therapeutics former president Sean Maduck sells $2.05M in stock
      Nov 5Investing.comCORT
      Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...

      Corcept Therapeutics Inc (CORT) posted $340.5 million in Q3 2026 revenue on explosive oncology growth, reiterated its full-year guidance, and now awaits a December 17 FDA decision on relacorilant.

      Nov 4Yahoo FinanceCORT
      Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 4The Globe and MailCORT
      Corcept Therapeutics Incorporated Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceCORT
      CORT Q3 2026 deep dive: rapid Lifyorli uptake and pipeline expansion shape outlook
      Nov 4BarchartCORT
      Corcept Therapeutics Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceCORT
      Earnings call transcript: Corcept beats Q3 2026 estimates, shares slip after hours
      Nov 3Investing.comCORT
      Corcept Therapeutics Q3 2026 Earnings Call Transcript
      Nov 3BenzingaCORT
      Corcept Therapeutics falls on guidance despite earnings beat
      Nov 3Yahoo FinanceCORT
      Corcept Therapeutics Q3 Earnings, Revenue Rise; Shares Fall After Hours
      Nov 3Yahoo FinanceCORT
      Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

      Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 3Yahoo FinanceCORT
      Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
      Nov 3Yahoo FinanceCORT
      Corcept earnings beat by $0.22, revenue topped estimates
      Nov 3Investing.comCORT
      Corcept: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceCORT
      Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
      Nov 3Yahoo FinanceCORT
      Corcept earnings on deck: Can Lifyorli sustain launch momentum?
      Nov 3Investing.comCORT
      Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
      Oct 27Yahoo FinanceCORT
      Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT)

      Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailCORT
      Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Corcept Therapeutics (CORT) and Incyte (INCY)

      Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailCORTTVTX
      What Corcept Therapeutics Stock Positive Trial Results Mean For Shareholders
      Oct 26Yahoo FinanceCORT
      Why Is Corcept Therapeutics Stock Trading Higher Today? - Corcept Therapeutics (NASDAQ:CORT)
      Oct 26BenzingaCORT
      Corcept Therapeutics Says Trial of Lifyorli Combination Slows Ovarian Cancer Growth
      Oct 26Yahoo FinanceCORT
      Why is Corcept Therapeutics stock rallying today?
      Oct 26Investing.comCORT
      Can Corcept Therapeutics Stock Rally 40% After This Dip?
      Oct 26Yahoo FinanceCORT
      Corcept reports phase 2 trial results for ovarian cancer drug
      Oct 26Investing.comCORT
      Corcept Therapeutics plunges 20% on Genmab cancer data (CORT:NASDAQ)
      Oct 23Seeking AlphaCORTGMAB
      U.S. Markets Declined Friday; Corcept Therapeutics Fell Furthest
      Oct 23Barron'sCORT
      Why is Corcept Therapeutics stock tumbling today?
      Oct 23Investing.comCORT
      2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
      Oct 20Yahoo FinanceCORT
      Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

      Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

      Oct 20The Globe and MailCORT
      The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics

      Detailed price information for Apa Corp (APA-Q) from The Globe and Mail including charting and trades.

      Oct 19The Globe and MailAPACORTHALO
      Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
      Oct 19Yahoo FinanceCORT
      Corcept Therapeutics director Wilson sells $1.15 million in shares
      Oct 16Investing.comCORT
      Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story
      Oct 15Yahoo FinanceCORT
      Corcept Therapeutics (CORT) Draws Options Attention, Is It Still 18% Below Fair Value?
      Oct 15Yahoo FinanceCORT
      Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock?
      Oct 13Yahoo FinanceCORT
      Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
      Oct 12ReutersCORTTEVA
      Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT)

      Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailCORT
      IBD Stock Of The Day Corcept Setting Up Amid Booming Growth

      Corcept is Tuesday's IBD Stock Of The Day. Shares hit the skids on a medical sell-off, but stayed above the 21-day line.

      Oct 6Investor's Business DailyCORT
      Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing
      Oct 6Yahoo FinanceCORT
      Corcept Therapeutics Insider Sold Shares Worth $1,160,731, According to a Recent SEC Filing
      Oct 6Yahoo FinanceCORT
      Corcept Therapeutics president Sean Maduck sells $2.9 million in stock
      Oct 6Investing.comCORT
      Corcept Therapeutics president sells $967k in shares
      Oct 6Investing.comCORT
      Corcept Therapeutics chief accounting officer sells $1.16m
      Oct 6Investing.comCORT

      This is the newest page. Registered accounts read further back.